Orthocell has appointed four US distributors for its flagship nerve repair product Remplir™, enabling the commencement of commercial distribution into the US.
These distributors are experienced nerve specialists operating in Michigan, Virginia, Colorado and Indiana states. Drawing on their existing relationships with surgeons and hospitals, they will market and distribute Remplir for use in the surgical repair of peripheral nerves across their respective geographic regions, expanding the network of referring plastic and orthopaedic surgeons.
These appointments follow receipt of US FDA 510(k) clearance for Remplir earlier this month, marking the Company’s strategic entry into the $1.6 billion US nerve repair market.
Orthocell CEO and MD, Paul Anderson, said:
“We have been working closely with a number of distributors in the United States in advance of our recently received FDA 510(k) clearance and welcome them on board as our first partners in the US. We are looking forward to our distributor network helping us to drive Remplir sales, and as a company, we are primed and ready to deliver Remplir into the US.”